B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
-5.73%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.16B
AUM Growth
+$104M
(+3.4%)
Cap. Flow
-$1.09B
Cap. Flow
% of AUM
-34.59%
Top 10 Holdings %
Top 10 Hldgs %
35.35%
Holding
97
New
14
Increased
28
Reduced
11
Closed
11
Avg Time Held
0.5
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bicycle Therapeutics
BCYC
|
+$29.5M |
| 2 |
89bio
ETNB
|
+$26.7M |
| 3 |
Immunocore
IMCR
|
+$26M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$25.8M |
| 5 |
Inspire Medical Systems
INSP
|
+$25.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DICE Therapeutics, Inc. Common Stock
DICE
|
+$47.8M |
| 2 |
Biogen
BIIB
|
+$34.7M |
| 3 |
Align Technology
ALGN
|
+$34.1M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$30.1M |
| 5 |
Glaukos
GKOS
|
+$26M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.8% |
| 2 | Miscellaneous | 47.89% |
| 3 | Consumer Staples | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Pulmonx
LUNG
$76.4M
| $10.2M | 0.32% |
988,559
-10,803
| -1% | -$125K |
2022 Q4
3 quarters
|
|
52
SkinHealth Systems
SKIN
$75.2M
| $9.79M | 0.31% |
+81,312
| New | +$11.4M |
2023 Q3
0 quarters
|
|
53
Amgen
AMGN
$230B
| $9.73M | 0.31% |
+36,200
| New | +$9.03M |
2023 Q3
0 quarters
|
|
|
SGEN
54
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.02M | 0.28% |
42,497
| – | – |
2023 Q2
1 quarter
|
|
55
Krystal Biotech
KRYS
$9.79B
| $8.99M | 0.28% |
77,497
-163,902
| -68% | -$20M |
2022 Q4
3 quarters
|
|
56
Replimune Group
REPL
$1.07B
| $8.34M | 0.26% |
487,520
| – | – |
2022 Q4
3 quarters
|
|
57
Agenus
AGEN
$294M
| $7.13M | 0.23% |
315,352
+80,455
| +34% | +$2.28M |
2023 Q2
1 quarter
|
|
58
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $6.17M | 0.19% |
+277,778
| New | +$5.83M |
2023 Q3
0 quarters
|
|
59
ALX Oncology
ALXO
$124M
| $6M | 0.19% |
1,249,900
| – | – |
2022 Q4
3 quarters
|
|
60
Adaptive Biotechnologies
ADPT
$4.09B
| $5.27M | 0.17% |
967,690
+319,239
| +49% | +$2.11M |
2023 Q1
2 quarters
|
|
|
61
Aclaris Therapeutics
ACRS
$498M
| – | – |
-2,901,194
| Closed | -$30.1M | – |
|
62
Alphatec Holdings
ATEC
$1.61B
| – | – |
-25,431
| Closed | -$457K | – |
|
|
63
Biogen
BIIB
$34.4B
| – | – |
-121,942
| Closed | -$34.7M | – |
|
64
DELISTED
Crinetics Pharmaceuticals
CRNX
| – | – |
-650,312
| Closed | -$11.7M | – |
|
65
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-895,949
| Closed | -$1.25M | – |
|
66
DELISTED
Merus
MRUS
| $0 | ﹤0.01% |
1,901,337
+358,175
| +23% | +$8.69M |
2022 Q4
3 quarters
|
|
67
Nuvation Bio
NUVB
$1.64B
| – | – |
-4,122,900
| Closed | -$7.42M | – |
|
68
Rhythm Pharmaceuticals
RYTM
$5.97B
| – | – |
-843,087
| Closed | -$13.9M | – |
|
69
DELISTED
ACELYRIN
SLRN
| – | – |
-500,000
| Closed | -$10.4M | – |
|
70
Vir Biotechnology
VIR
$1.76B
| – | – |
-728,549
| Closed | -$17.9M | – |
|
|
MRTX
71
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-240,625
| Closed | -$8.69M | – |
|
|
72
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| – | – |
-1,029,901
| Closed | -$47.8M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q3 2023 Portfolio in Review
As of Q3 2023, Braidwell held 97 positions worth $3.16B, up 3.4% from $3.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Braidwell withdrew a net $1.09B in Q3 2023, closing 11 positions and reducing 11 holdings. Its most notable exit was DICE Therapeutics, Inc. Common Stock, an estimated $47.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 54% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Braidwell opened a new position in Bicycle Therapeutics worth $25.9M.
- Braidwell's largest Q3 2023 buy was Bicycle Therapeutics: 1,289,872 shares worth $25.9M.
- Braidwell added most to Immunocore in Q3 2023, an estimated $26M increase.
- Braidwell's biggest Q3 2023 reduction was Align Technology, cutting an estimated $34.1M.
- Braidwell fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $47.8M.
- Braidwell's ten largest holdings make up 35% of its $3.16B portfolio in Q3 2023.
- Braidwell opened 14 new positions and closed 11 in Q3 2023.
- Braidwell's portfolio value rose 3.4% quarter-over-quarter to $3.16B.
Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.